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Abstract 
Although colorectal cancer (CRC) is the most common cancer type in Lynch syndrome (LS) 
families, patients have also increased lifetime risk of other types of tumors. The accumulated risk of 
pancreatic cancer (PC) in LS patients is around 3.7% and developed tumors often present a 
characteristically medullary appearance with prominent lymphocytic infiltration. LS patients are 
considered in high risk for PC development as they present 8.6-fold increase compared with the 
general population. 
Here we review PC cases reported in LS patients and current management guidelines. Literature 
data show that LS is clearly associated with PC and recent publications also demonstrated a 
connection with pancreatic neoplasic precursor lesions such as intraductal papillary mucinous 
neoplasms (IPMN) in these patients.  
While screening techniques are well established for CRC detection, clear strategies are not yet 
uniform for PC. Magnetic resonance imaging (MRI) and/or endoscopic ultrasound every 1-2 years 
in MMR mutation carriers with PC in a first or second-degree relative is recommended. 
Better pancreatic cancer detection strategies should be urgently defined due to the importance of 
early diagnosis in this disease. 
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Introduction 
Pancreatic cancer (PC) is one of the neoplasias 
with worse prognosis and despite the increased 
efforts in research, progress in patient’s survival has 
remained slow with a 5-year survival rate estimated 
in 2016 of 8%1. It is expected that PC death rate will 
increase being the second leading cause of 
cancer-related death by 20302. 
Since pancreatic ductal adenocarcinoma (PDAC) 
is the predominant pancreatic tumor type, we will 
refer to this pathology as PC.  
Majority of PC cases (>80%) are considered 
sporadic, due to sporadic mutations. The main 
modifiable risk factors are smoking, obesity, diabetes 
mellitus, non-O blood group, Helicobacter pylori 
infection and chronic pancreatitis. While all of these 
factors increase risk up to 2 fold, chronic pancreatitis 
could give up to 13.3 fold of higher risk3. 
Hereditary pancreatic cancer (accounts for 5-10% of 
cases) is defined as a genetic syndrome with an 
identifiable gene mutation associated with an 
increased risk for PC. These mutations are principally 
BRCA2, p16, ATM, STK11, PRSS1/PRSS2, SPINKI, 
PALB2 and DNA mismatch repair genes (MMR)- each 
one associated to increased risk for PC development4. 
However, BRCA2 is probably the most common 
inherited disorder.  
Considering pathologies, individuals should be 
considered to be at risk for PC if they have hereditary 
pancreatitis, cystic fibrosis or other PC-related 
syndromes. These other syndromes linked to PC risk 
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include Lynch syndrome (LS), Peutz-Jeghers 
syndrome (PJS), Familial atypical multiple mole 
melanoma syndrome (FAMMM) and Li-Fraumeni 
syndrome. 
Familial Pancreatic Cancer (FPC) is defined as a 
family with at least one pair of first-degree relatives 
(parent-child or sibling pair) with PC without an 
identifiable syndrome in the family5.  
Lynch Syndrome Definition and Types 
LS, formerly known as hereditary nonpolyposis 
colorectal cancer or HNPCC was firstly described by 
Warthin in 1913 and it is an autosomal dominant 
disease caused by germline mutation in MMR genes 
MLH1, MSH2, MSH6 and PMS2, or by germline 
mutation in EPCAM which causes epigenetic 
silencing of MSH2 6, 7. 
LS is suspected on the basis of patient and family 
history, MMR protein expression pattern and 
Microsatellite instability (MSI) phenotype. The 
incidence of this syndrome has been postulated to be 
between 1:660 and 1:20008. 
MMR mutation is generally inherited from one 
parent and patient has every cell in the body with one 
defective copy of the particular gene and a fully 
functional copy that maintains DNA repair in cells. A 
cell develops a DNA repair defect only when this 
functional copy of the gene becomes nonfunctional as 
a result of a random somatic mutation9. 
There are two forms of LS: Type I, the one 
limited to colon specific syndrome and type II, that 
includes cancer in different anatomic sites such as 
endometry, ovary, pancreas, etc. 
As determined in the ACG Clinical guideline: 
genetic testing and management of hereditary 
gastrointestinal cancer syndromes, LS should be 
considered in individuals whose tumors show 
evidence of MMR deficiency (without the presence of 
a BRAF mutation or MLH1 promoter 
hypermethylation), and those whose personal and/or 
family history fullfill the Amsterdam criteria, 
Bethesda Guidelines (Available from 
http://www.nccn.org/professionals/physician_gls/f
_guidelines.asp) or who have a ≥5% risk of carrying a 
germline mutation based on available prediction 
models10, 11. 
The primary strategy currently used in routine 
practice to identify LS patients is tumor sample 
evaluation for evidence of high level MSI (MSI-H) 
and/or DNA MMR deficiency (MMR-D)10, 11. Several 
studies have consistently demonstrated that universal 
tumor testing- mostly by using Polymerase chain 
reaction (PCR) for MSI testing and 
immunohistochemical staining for MMR protein 
expression of all CRC tumors is a more effective way 
to screen LS compared to previous guidelines based 
on Bethesda guidelines or Amsterdam criteria. 
However, successful results depend on availability of 
both, healthy and cancer relatives undergoing genetic 
testing12, 13. 
LS accounts for approximately 2–5% of all 
colorectal cancers (CRC) diagnosis and is the most 
common cause of inherited colon cancer conferring a 
lifetime risk between 52-82% with a mean diagnosis 
age of 44 years. However, endometrial tumors occur 
with a similar frequency to colon cancer in woman 
with LS. LS also confers an increased risk of other 
types of tumors such as endometrial (lifetime risk 
25-60%), ovarian (4-12%), gastric (6-13%), pancreatic 
(1.3-4%), ciliary tract and kidney cancer14-17. This 
means that LS patients frequently develop colorectal 
cancer before the age of 50 and approximately 
one-third of them develop another LS typical tumor 
within 10 years18. 
In this review, we will focus on PC- cases 
reported, increased risk and current management 
guidelines.  
Genetic association of LS and PC 
LS is an autosomal dominant hereditary disorder 
due to mutation in a mismatch repair (MMR) genes. 
In PC cases derived from LS, mutations have been 
specifically described in genes encoding DNA 
reparation proteins: MLH1 (mutL homolog 1), MSH2, 
MSH6 (mutS homolog 2 y 6, respectively), PMS2 
(PMS1 homolog 2, mismatch repair system 
component). Less frequently, PALB2 (partner and 
localizer of BRCA2) and EPCAM (Epithelial cell 
adhesion molecule) gene located upstream of MSH2 
have been seen in LS patients diagnosed with PC. 
EPCAM deletions lead to a transcriptional 
read-through, hypermethylation and subsequent 
silencing MSH2 and are estimated to cause Lynch 
syndrome in ~20–25% of patients with 
MSH2-negative cancers, but no detectable MSH2 
germline mutation6. 
Mutations in the MLH1 and MSH2 genes have 
more effect on DNA repair than mutations in MSH6 
or PALB2. Patients with an MLH1 or MSH2 mutation 
therefore have a substantially higher risk of tumors 
than patients with an MSH6 mutation. The risk of 
patients with a PMS2 mutation seems to be even 
lower than that of patients with an MSH6 mutation9.  
As it occurs in other type of LS tumors, defect in 
the DNA mismatch repair system increase the error 
rate of replication by 100 to 1000 fold. Areas of the 
genome that contain repetitive sequences 
(microsatellites) are particularly susceptible to 
insertion and deletion of bases during the replication 
process. Errors produces in the DNA sequence are 
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recognized by proteins such as MSH2 or MHS6 19.  
Typically these alterations are germline 
mutations and genetic testing of patients should 
include germline mutation genetic testing for the 
MLH1, MSH2, MSH6, PMS2, and/or EPCAM genes or 
the altered gene(s) indicated by immunochemistry 
testing11. 
MSI-H tumors have been associated with poor 
differentiation and the presence of wild type KRAS 
and p53 genes (frequently mutated in sporadic cases 
os PC). Moreover, patients with MSI-H tumors have 
longer overall survival compared to those with MSI-L 
or MSS tumors20. Additionally, some authors support 
that MSI and MMR loss of expression in LS is 
associated to medullary carcinomas of pancreas17, 21.  
Next generation data could help to identify other 
mutations and epigenetic modifications occurring in 
tumor suppressor genes and oncogenes finally 
responsible for neoplastic transformation. 
Confirmatory statements about mutational status in 
genes frequently alternated in PC such as KRAS, 
SMAD4, TP53, CDKN2A are still needed.  
Reported cases of PC in the literature 
The accumulated risk of PC in LS patients is 
around 3.7%22 (it is 1.5% in general population)17, 23, 24. 
It has been described that pancreatic tumors 
developed by LS patients often have a 
characteristically medullary appearance21, 25, with 
prominent lymphocytic infiltration and MSI26. 
When a search for ‘’Lynch syndrome & 
pancreatic cancer’’ was performed, as shown in 
Figure 1, 106 records were identified from PubMed 
database. If research was done for terms ‘’hereditary 
nonpolyposis colorectal cancer & pancreatic cancer’’ 
79 records were found; however, all of them except 
one (non-specific) were duplicated of those included 
in the 106. 
Considering the 106 cases after removing 71 
‘’related but not specific or irrelevant’’ records, we 
found 17 review/guidelines, 3 IPMN-related cases 
and 15 relevant descriptive cases. Here, we present 
summary of the total 18 reporting PC cases in LS 
patients. A note with these studies is presented in 
Table 1. 
Lynch et al. were the first in 1985 reporting an 
increased risk of developing PC in LS families27. They 
described a kindred with vertical transmission of 
cancer through 5 generations in which HNPCC and 
PC was shared. 
Since 1985, several authors have described cases 
and incidence of PC around the world. Wei et al.28 in 
2002 reviewed 10 Taiwanese families including a total 
of 202 individuals meeting Amsterdam criteria for LS 
and they found one PC case. Geary et al. in 2008 
examined 982 cancers in 723 individuals who 
belonged to 130 families and found 22 PC, 14 of them 
diagnosed before the age of 6029. In this series, PC was 
the third more frequent after colorectal and 
endometrial cancer. In 2009, Gargiulo et al.30 noted 
that estimated frequency of LS was small since among 
135 PC patients they only found 19 LS carriers. 
Kastrinos et al. analyzed 6342 individuals from 147 
families with MMR gene mutations. Thirty-one 
families (21.1%) reported at 
least 1 PC case. Forty-seven 
pancreatic cancers were 
reported (21 men and 26 
women), with no sex-related 
difference in age of diagnosis 
(51.5 vs 56.5 years for men 
and women, respectively). 
The cumulative risk of PC in 
these families with gene 
mutations was 1.31% up to 
age 50 years and 3.68% up to 
age  of 70 years, which 
represents an 8.6-fold 
increase compared with the 
general population17. In 2011 
Kempers et al.31 evaluated 
194 carriers of an EPCAM 
deletion and four were 
found to have PC and Lindor 
et al. reported a family in 
which MSH2 P349L missense 
alteration cosegregatated 
 
Figure 1. Flow diagram for selected studies 
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with PC in 3 first degree relatives (FDR)32. Recently, in 
early 2017 Dymerska et al.33 reported the presence of a 
founder mutation (c.858+2478_*4507del) in eight 
Polish families. Laghi et al. in 2012 evaluated 338 
consecutive PDAC in German and Italian centers 
concluding that MSI prevalence is negligible for 
sporadic PC. Differently, the prevalence of PC is 2.5% 
in LS patients34.  
In 2015, Salo-Mullen et al. published a study in 
which they analyzed mutations in 159 PC patients 
identifying 24 pathogenic mutations including 
BRCA2, BRCA1, p16, PALB2 and LS35. Four different 
mutations in MSH2 and MLH1 were found in these 
LS patients and they were especially frequent in early 
new onset disease. 
Catts et al.36 conducted a retrospective review of 
PC families in US from 2002 to 2013. They analyzed 
familial pancreatic cancer individuals (including FPC 
criteria subjects, individuals with only one 
first-degree relative affected by PC [first-degree 
families] and PC affected). 175 families completed a 
testing: 46 being FPC and 99 first-degree families. 16 
out 46 FPC went LS testing and pathogenic mutations 
in MMR were identified in 2 of them: one in MLH1 
and one in MSH2. 32 out the 99 first-degree families 
went LS testing and 4 of them had pathogenic 
mutation: three in MLH1 and one in MSH6. Authors 
concluded that in FPC, breast and ovarian cancer and 
then LS are the most prevalent syndromes leading to 
PC. Cajal et al.37 identified a mutation n 
c.2252_2253delAA, p.Lys751Serfs*3 en el exón 19 del 
gen MLH1 in an Italian patient. This mutation was 
previously noted as pathogenic in Korea, Denmark, 
United Kingdom, Germany and Australia and 
described by Borrelli et al.38 in a MLH1 mutation 
(c2253_2253delAA) that co-segregates with LS cancer 
in 11 unrelated families. All families had at least one 
colon cancer diagnosed before age of 50 and one case 
with multiple LS related tumors. Interestingly, a 
statistically significant association was found with 
higher frequency of PC compared to families with 
other MLH1 mutations.  
While all the publications presented above 
reported an increased rate of pancreatic cancer in LS 
families and patients, another study published by 
Barrow et al.16 in 2009 observed no excess risk. 
Additionally, two additional studies in the literature 
reported in the eighties and nineties found no high 
correlation between LS and PC since in a study of 40 
Finnish LS kindreds, only 6 out of 243 carriers with 
clinically or histologically cancer had PC39. 
Conversely, no PC was found in a series of 22 Dutch 
LS families with at least one person diagnosed with 
PC40. 
Although LS has been clearly associated with PC 
(understood as Pancreatic Ductal 
Adenocarcinoma-PDAC), no clear connection has 
been established with pancreatic neoplasic precursor 
lesions in these patients. Only a few recent 
publications have demonstrated that intraductal 
papillary mucinous neoplasm (IPMN) could be LS 
related and consequently, these lesions should be 
carefully considered at patient’s screening. 
 
Table 1. Most relevant studies supporting evidence of PC in LS patients. 
Most relevant cases described 
in the literature 
Genetic Evidence Associated 
Disease 
Country Number LS patients / Number PC 
cases 
# Reference 
Lynch et al. 1985 ns PC USA (Nebraska) Family Case Report (3 PC) 27 
Wei et al. 2002 ns Taiwan 202 LS/1 PC 28 
Banville et al. 2006 MSH2, MLH1 nonsense mutations Ireland Case Report 21 
Geary et al. 2008 ns United Kingdom 130 LS/22PC 29 
Barrow et al. 2009 ns United Kingdom 938 LS /2 PC 16 
Vergara-Fernández et al. 2009 ns Mexico Case Report 25 
Gargiulo et al. 2009 ns Italy ∗135 PC/19 LS 30 
Kastrinos et al. 2009 MSH2, MLH1, MSH6 mutations USA (Massachusets) 147 LS families/47 PC 17 
Kempers et al. 2011 EPCAM deletions The Netherlands 194 EPCAM deletion carriers/ 4 PC 31 
Lindor et al. 2011 MSH2 (P349L) missense alteration  USA (Northern 
European ancestry) 
Family Case Report (3 PC) 32 
Laghi et al. 2012 MLH1 deficiency and MLH1 
methylation 
Italy & Germany 203 LS/5PC 34 
Borelli et al. 2014 MLH1 (c.2252_2253delAA) mutation Italy 67 LS/ 5 PC 38 
Salo-Mullen et al. 2015 MHS2, MLH1, MSH6 mutations USA (New York) *159 PC/4 LS 35 
Catts et al. 2016 MSH2, MLH1 mutations USA (Delaware) 16 FPC families / 2 LS 36 
Cajal et al. 2016  MLH1 (c.2252_2253delAA) mutation Italy & Spain Case Report 37 
Sparr et al. 2009 MSH2, MSH6 mutations IPMN USA (Massachusets) Case Report 41 
Flanagan et al. 2015 MSH2 mutation USA (Wasintong) Case Report 42 
Lee et al. 2015 MHS2, MSH6 mutation? South Korea Case Report 43 
Dymerska et a. 2017 EPCAM mutation  Poland Family Case Report (1 PC) 33 
Ns, not specified. PC, Pancreatic Cancer; IPMN, intraductal papillary mucinous neoplasms. * LS mutations (cases) were evaluated in PC patients. 
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Firstly, in 2009, Sparr et al.41 described the case of 
a 61-year old woman with LS and multiple cancers 
including colorectal adenocarcinoma and IPMN. 
More recently, a case of a 58 year-old woman was 
reported by Flanagan et al. This LS patient (exon 1 
deletion in MSH2 that was classified as a suspected 
deleterious change) was diagnosed firstly with 
colorectal cancer, then uterine and breast cancer and 
finally CT images showed a progression of main duct 
IPMN to invasive pancreatic ductal adenocarcinoma. 
Due to LS and previous history of cancer, distal 
pancreatectomy was indicated. However, MMR 
immunohistochemical stain was negative for MLH1, 
PMS2, MSH2 and MSH642. Finally, Lee et al. reported 
a case of a 49 year-old woman diagnosed with LS, past 
history of colon and endometrial carcinoma in which 
IPMN originated from the ideal heterotopic pancreas 
was surgically resected. It was positive for 
MLH1/PMS2 and negative for MSH2/MSH643. 
All of this data suggest that IPMN are part of the 
spectrum of lesions found in LS. 
Moreover, Acinar cell carcinoma (ACC)- a rare 
pancreatic malignancy has been documented by Liu 
et al.44 in 36 ACC cases, of which 5 were MMR 
deficient and 2 out of these 5 were LS. ACC was also 
reported by Karamurzin et al.45 in a single case. 
Strategies for PC in LS patients 
It is well known that screening general 
population for PC is not cost-effective and screening 
strategy has been only confined to High Risk (HR) 
Population- defined as subjects with 6-8 times higher 
risk of having PC compared with age-matched 
controls. This HR group, as established now, includes 
individuals with 2 first-degree relatives with PC 
which is the cohort currently screened for familial 
PC46. Additionally, and still controversial is to include 
new onset diabetes subjects older than 50 years, which 
as demonstrated by Chari et al.47 have 6-8 fold higher 
probability of being diagnosed with PC, as HR. This 
last scenario is nowadays more accepted in US than in 
Europe or any other country. 
For healthy individuals who have a germline 
mutation in a gene linked to PC risk, as it is the case of 
LS, the priority is to manage and reduce PC risk due 
to the importance of early diagnosis in this disease. 
However, in this case of healthy LS individuals, 
factual risk and clear strategies are not yet uniform 
and well-defined. 
If, as demonstrated by some authors, patients 
with LS have an 8.6-fold increased risk of developing 
PDAC compared to the general population17, they 
should then considered as HR subjects and 
consequently, enter clearly into screening programs.  
In one side, it has been purposed in 2011 by the 
International Cancer of the pancreas screening 
(CAPS) consortium that LS patients and one 
first-degree relative with PC should be candidates for 
screening48. On the other side, it is indicated in the 
summary of recommendations by Syngal et al. about 
how to manage extracolonic neoplasia screening in LS 
patients: ‘’Screening beyond population-based 
recommendations for cancers of the urinary tract, 
pancreas, prostate, and breast is not recommended 
unless there is a family history of the specific cancers 
(conditional recommendation, low quality of 
evidence)’’. In this case (family history demonstrated), 
it can be considered a magnetic resonance imaging 
(MRI) and/or endoscopic ultrasound every 1-2 years 
in MMR mutation carriers with PC in a first 48 or 
second-degree relative11 depending on the 
recommendation guides (Table 2).  
The frequency and age to begin surveillance are 
not yet well defined. Most centers utilize endoscopic 
ultrasound and/or MRI surveillance programs, both 
of which detect pancreatic lesions better than CT49. 
Past screening efforts, mostly using HR- FPC, PJS and 
FAMMM patients have demonstrated diagnostic 
yields from 1.1 to 50%, depending on their definition 
of yield3. However, since it is well-known that in 
general terms there is not effective screening test for 
this malignancy, some authors considerer PC a ‘’rare 
LS related tumor’’ and no specific screening measures 
other than abdominal ultrasound and general 
physical examination is recommended9.  
 
Table 2. Guidelines for PC screening in LS patients. 
Management strategy for PC Screening Technique Guidelines/Author recommending Year 
‘’LS individuals with at least one affected FDR with 
PC’’ 
MRI/EUS/CT/ERCP* CAPS International cancer of pancreas screening/Canto 
et. al. 
2011 
‘’LS-MMR mutation carriers with PC in a FDR’’ 
(conditional recommendation; very low quality of 
evidence) 
MRI/EUS ACG Clinical Guideline/Syngal et. al 2015 
CT, Computed tomography; ERCP, Endoscopic retrograde cholangiopancreatography; LS, Lynch syndrome; FDR, First degree relative; MSI, Magnetic resonance imaging; 
PC, Pancreatic cancer;  
* Initial screening should include (multiple answers allowed): EUS 83.7%, MRI 73.5%, CT 26.5%, abdominal ultrasound 14.3%, ERCP 2.0%. B2 When previous screening did 
not detect an abnormality that met criteria for shortening of the interval or surgical resection, follow-up screening should include (multiple answers allowed): EUS 79.6% 
MRI 69.4%, CT 22.4%, abdominal ultrasound 4.1%, ERCP 2.0% 
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In general it can be said that literature contains 
little reliable information on screening for other 
tumors than colorectal and ovarian/endometrio in LS 
patients. Prospective data indicated that screening 
colonoscopies beginning in the early 20s can 
markedly reduce colorectal cancer incidence and 
colorectal cancer-related mortality in individuals with 
LS50. For women with LS, risk-reducing hysterectomy 
and salpingo-oophorectomy can drastically reduce 
the risk of endometrial and ovarian cancers51. Being 
PC less frequent than these other tumor types, more 
investigation to reach consensus is needed. PancPro 
(https://www4.utsouthwestern.edu/breasthealth/ca
gene) is a clinical prediction model that uses personal 
and family history data, including prior genetic 
testing results, to estimate an individual’s future risk 
of developing pancreatic cancer. 
Discussion and conclusion 
PC is a leading cause of cancer death and very 
few patients are candidates for the only curative 
option-the surgery. Screening of HR patients 
amenable to surgical resection should be a priority.  
It must be recognized that based on the 
literature, Peutz-Jeghers syndrome (132 fold), 
FAMMM syndrome (47 fold) or hereditary 
pancreatitis (69 fold) confer a bigger increase in PC 
risk compared to LS (8.6 fold)3. This is, although PC is 
not one of the top cancer types in LS patients (lower 
incidence than colorectal and endometrial tumors), 
still these patients are considered in high risk- as they 
present 8.6-fold increase compared with the general 
population. 
As it has been presented above, most of the 
studies published in the literature (including patients 
from USA, Europe and Asia) demonstrate a good 
association of PC in LS kindreds. This review 
summarizes the studies that should serve to support 
evidence of PC risk in LS patients. 
Accepting this evidence and the clinical need for 
PC screening in LS individuals, only a few guidelines 
describe further management strategies. They 
recommend screening LS individuals MMR carriers 
with at least one PC case in a FDR. Unfortunately, 
adequate screening technique for PC does not 
currently exist and further research must be done and 
options for these patients include MRI and EUS. 
However, optimal interval for screening and the 
management of PC precursor lesions is still 
controversial52. Moreover, there is an urgent need to 
find new biomarkers that could help to screen HR 
individuals53, including LS patients. How clinicians 
should fully address PC screening and management is 
still unclear as many uncertainties in PC and LS 
remain. 
Recent reviews highlight the increasingly 
recognized role of genetics in the development of PC 
and associated syndromes. Given the poor prognosis 
of PC, the development of next-generation genome 
sequencing will show additional alterations that 
combined with more powerful screening and 
surveillance tools may lead to an improved survival54. 
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